Showing results (101-110 of 251) with videos related to
Sort By:
Pageof 26
Clinical Therapeutics|October 26, 2000
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaS R David, C C Taylor, B J Kinon, et al.International Clinical Psychopharmacology|September 19, 2000
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sampleS H Hamilton, E T Edgell, D A Revicki, et al.Brain Research|January 8, 1999
The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteersI Elman, L Sokoloff, C M Adler, et al.The Journal of Physical Chemistry. A|February 12, 2025
Optical Spectrum and Photochemistry of Si2O2Taarna Studemund, Kai Pollow, Marko Förstel, et al.General Physiology and Biophysics|January 11, 2005
Functional fluo-3/AM assay on P-glycoprotein transport activity in L1210/VCR cells by confocal microscopyJ Orlický, Z Sulová, I Dovinová, et al.Bratislavske Lekarske Listy|March 1, 1990
[The role of Na(+) pump inhibition induced by Ca2(+) ions in the development of pathologic changes during calcium overload in myocardial cells]A Breier, V Durisová, R Monosíková, et al.Neuropsychiatry, Neuropsychology, and Behavioral Neurology|January 25, 2000
The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revisedL P Kestler, A K Malhotra, C Finch, et al.General Physiology and Biophysics|June 1, 1985
Exaprolol as a modulator of heart sarcolemmal (Na+ + K+)-ATPase. Evidence for interaction with an essential sulfhydryl group in the catalytic centre of the enzymeA Dzurba, A Ziegelhöffer, L Schmidtová, et al.General Physiology and Biophysics|August 1, 1985
Quantitative relationship between the protein secondary structure in cardiac sarcolemma and the activity of the membrane-bound Ca2+-ATPaseN Vrbjar, A Ziegelhöffer, A Breier, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 18, 2001
SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistanceM Barancík, V Bohácová, J Kvackajová, et al.Pageof 26